NMOSD IgG Impact Retinal Cells in Murine Retinal Explants.
Müller cell
NMOSD
autoantibodies
chemokine
complement
local
mouse retinal explants
retina
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
07 Sep 2023
07 Sep 2023
Historique:
received:
18
07
2023
revised:
29
08
2023
accepted:
05
09
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Neuromyelitis optica spectrum disorders (NMOSD) are chronic inflammatory diseases of the central nervous system, characterized by autoantibodies against aquaporin-4. The symptoms primarily involve severe optic neuritis and longitudinally extensive transverse myelitis. Although the disease progression is typically relapse-dependent, recent studies revealed retinal neuroaxonal degeneration unrelated to relapse activity, potentially due to anti-aquaporin-4-positive antibodies interacting with retinal glial cells such as Müller cells. In this exploratory study, we analysed the response of mouse retinal explants to NMOSD immunoglobulins (IgG). Mouse retinal explants were treated with purified IgG from patient or control sera for one and three days. We characterized tissue response patterns through morphological changes, chemokine secretion, and complement expression. Mouse retinal explants exhibited a basic proinflammatory response ex vivo, modified by IgG addition. NMOSD IgG, unlike control IgG, increased gliosis and decreased chemokine release (CCL2, CCL3, CCL4, and CXCL-10). Complement component expression by retinal cells remained unaltered by either IgG fraction. We conclude that human NMOSD IgG can possibly bind in the mouse retina, altering the local cellular environment. This intraretinal stress may contribute to retinal degeneration independent of relapse activity in NMOSD, suggesting a primary retinopathy.
Identifiants
pubmed: 37754247
pii: cimb45090463
doi: 10.3390/cimb45090463
pmc: PMC10529972
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7319-7335Subventions
Organisme : Hertie Foundation
ID : P1210070
Références
Neurology. 2013 Apr 9;80(15):1406-14
pubmed: 23516321
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
Exp Eye Res. 2016 Jun;147:31-36
pubmed: 27109031
Ophthalmology. 2019 Jun;126(6):801-810
pubmed: 30711604
Expert Opin Emerg Drugs. 2022 Mar;27(1):91-98
pubmed: 35341428
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 23;7(5):
pubmed: 32576604
Front Immunol. 2015 Jun 02;6:262
pubmed: 26082779
Cell Rep. 2019 Nov 26;29(9):2835-2848.e4
pubmed: 31775049
Ann Neurol. 2016 Apr;79(4):605-24
pubmed: 26836302
Ann Neurol. 2009 Nov;66(5):630-43
pubmed: 19937948
Mult Scler. 2007 Jul;13(6):701-7
pubmed: 17613596
Clin Ophthalmol. 2022 Dec 10;16:4075-4087
pubmed: 36532823
PLoS One. 2013 Apr 18;8(4):e61835
pubmed: 23637915
Mol Neurobiol. 2021 Oct;58(10):5178-5193
pubmed: 34263427
Expert Rev Clin Immunol. 2022 Sep;18(9):933-945
pubmed: 35899480
J Neurol. 2016 Jul;263(7):1343-8
pubmed: 27142716
Prog Retin Eye Res. 2006 Jul;25(4):397-424
pubmed: 16839797
Int J Mol Sci. 2016 Jul 16;17(7):
pubmed: 27438827
Brain. 2010 Feb;133(Pt 2):349-61
pubmed: 20047900
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 4;7(5):
pubmed: 32753407
Nat Rev Dis Primers. 2020 Oct 22;6(1):85
pubmed: 33093467
Invest Ophthalmol Vis Sci. 2012 Nov 09;53(12):7567-75
pubmed: 23010641
Neuropsychiatr Dis Treat. 2019 Jan 21;15:303-310
pubmed: 30718956
J Neuroinflammation. 2016 Oct 20;13(1):275
pubmed: 27765056
Front Neurol. 2018 Feb 12;9:44
pubmed: 29497397
Front Neurol. 2021 Jul 23;12:703249
pubmed: 34367056
J Neuroinflammation. 2014 Jan 27;11:16
pubmed: 24468108
J Extracell Vesicles. 2022 Sep;11(9):e12254
pubmed: 36043482
J Neurosci. 2015 Sep 30;35(39):13525-37
pubmed: 26424896
Antioxidants (Basel). 2019 Nov 13;8(11):
pubmed: 31766295
Acta Neuropathol Commun. 2016 Aug 08;4(1):82
pubmed: 27503347
Front Neurol. 2021 Jul 19;12:669567
pubmed: 34349719
PLoS One. 2015 Jul 15;10(7):e0132800
pubmed: 26176960
Cytokine. 2013 Oct;64(1):90-6
pubmed: 23941778
J Neuroimmunol. 2018 May 15;318:45-52
pubmed: 29455925
Dev Biol. 2021 Dec;480:114-122
pubmed: 34529997
Eur J Med Res. 2022 Jun 21;27(1):96
pubmed: 35729649
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):1930-1940
pubmed: 28384714
PLoS One. 2020 Sep 3;15(9):e0238301
pubmed: 32881954
Mult Scler. 2021 Oct;27(11):1738-1748
pubmed: 33307967
Graefes Arch Clin Exp Ophthalmol. 2016 Dec;254(12):2469-2476
pubmed: 27812755
Prog Retin Eye Res. 2021 Mar;81:100880
pubmed: 32721458
Int Ophthalmol. 2023 Jun;43(6):1927-1933
pubmed: 36508058
Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3309-20
pubmed: 21345987
J Neuroimmunol. 2017 Dec 15;313:10-15
pubmed: 29153600
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669942
Am J Physiol. 1998 May;274(5):C1332-45
pubmed: 9612221
Front Pharmacol. 2021 Oct 29;12:771571
pubmed: 34776983
Front Immunol. 2022 Jun 15;13:895519
pubmed: 35784369
Sci Rep. 2022 Oct 20;12(1):17545
pubmed: 36266394
J Neuroimmunol. 2020 Feb 20;342:577194
pubmed: 32143071
Expert Opin Biol Ther. 2020 Sep;20(9):1061-1072
pubmed: 32228250
Glia. 2014 May;62(5):692-708
pubmed: 24492996
J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1259-1265
pubmed: 29921610
J Neurosci. 1998 Apr 1;18(7):2506-19
pubmed: 9502811
J Cell Commun Signal. 2019 Dec;13(4):451-462
pubmed: 30607767
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1245-50
pubmed: 22128336